BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 37306907)

  • 1. Oncolytic Virotherapy.
    Fatima M; Amraiz D; Navid MT
    Cancer Treat Res; 2023; 185():105-126. PubMed ID: 37306907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy.
    Chowaniec H; Ślubowska A; Mroczek M; Borowczyk M; Braszka M; Dworacki G; Dobosz P; Wichtowski M
    Front Immunol; 2024; 15():1375433. PubMed ID: 38576614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of oncolytic viruses for cancer therapy.
    Abd-Aziz N; Poh CL
    Transl Res; 2021 Nov; 237():98-123. PubMed ID: 33905949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy.
    Volovat SR; Scripcariu DV; Vasilache IA; Stolniceanu CR; Volovat C; Augustin IG; Volovat CC; Ostafe MR; Andreea-Voichița SG; Bejusca-Vieriu T; Lungulescu CV; Sur D; Boboc D
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.
    Jafari M; Kadkhodazadeh M; Shapourabadi MB; Goradel NH; Shokrgozar MA; Arashkia A; Abdoli S; Sharifzadeh Z
    Front Immunol; 2022; 13():1012806. PubMed ID: 36311790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment.
    Feola S; Russo S; Ylösmäki E; Cerullo V
    Pharmacol Ther; 2022 Aug; 236():108103. PubMed ID: 34954301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of oncolytic virotherapy: from genetic modification to combination therapy.
    Lan Q; Xia S; Wang Q; Xu W; Huang H; Jiang S; Lu L
    Front Med; 2020 Apr; 14(2):160-184. PubMed ID: 32146606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
    Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
    Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy.
    Wang X; Shen Y; Wan X; Hu X; Cai WQ; Wu Z; Xin Q; Liu X; Gui J; Xin HY; Xin HW
    J Transl Med; 2023 Jul; 21(1):500. PubMed ID: 37491263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
    Russell L; Peng KW; Russell SJ; Diaz RM
    BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic viruses and their application to cancer immunotherapy.
    Chiocca EA; Rabkin SD
    Cancer Immunol Res; 2014 Apr; 2(4):295-300. PubMed ID: 24764576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and application of oncolytic viruses for cancer immunotherapy.
    Ylösmäki E; Cerullo V
    Curr Opin Biotechnol; 2020 Oct; 65():25-36. PubMed ID: 31874424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving the therapeutic efficacy of oncolytic viruses for cancer: targeting macrophages.
    Shen Z; Liu X; Fan G; Na J; Liu Q; Lin F; Zhang Z; Zhong L
    J Transl Med; 2023 Nov; 21(1):842. PubMed ID: 37993941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fighting Cancer with Viruses: Oncolytic Virus Therapy in China.
    Wei D; Xu J; Liu XY; Chen ZN; Bian H
    Hum Gene Ther; 2018 Feb; 29(2):151-159. PubMed ID: 29284308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OV Modulators of the Paediatric Brain TIME: Current Status, Combination Strategies, Limitations and Future Directions.
    Vazaios K; van Berkum RE; Calkoen FG; van der Lugt J; Hulleman E
    Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic virotherapy in cancer treatment: challenges and optimization prospects.
    Chen L; Zuo M; Zhou Q; Wang Y
    Front Immunol; 2023; 14():1308890. PubMed ID: 38169820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements.
    Yun CO; Hong J; Yoon AR
    Front Immunol; 2022; 13():953410. PubMed ID: 36091031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia.
    Wang W; Liu S; Dai P; Yang N; Wang Y; Giese RA; Merghoub T; Wolchok J; Deng L
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic viruses in lung cancer treatment: a review article.
    Sakhi H; Arabi M; Ghaemi A; Movafagh A; Sheikhpour M
    Immunotherapy; 2024 Feb; 16(2):75-97. PubMed ID: 38112057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Research Advances of Clinical Application of Oncolytic Viruses in Treatment of Gynecologic Cancers.
    Deng M; Wang Q
    Curr Cancer Drug Targets; 2023; 23(7):505-523. PubMed ID: 36824004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.